GVR Report cover T-cell Therapy Market Size, Share & Trends Report

T-cell Therapy Market Size, Share & Trends Analysis Report By Modality, By Therapy (CAR T-cell, Tumor-Infiltrating Lymphocytes), By Indication (Hematologic Malignancies, Solid Tumors), By Region, And Segment Forecasts, 2021 - 2028

  • Report ID: GVR-3-68038-685-1
  • Number of Pages: 200
  • Format: Electronic (PDF)
  • Historical Range: 2017 - 2019
  • Industry: Healthcare

Report Overview

The global T-cell therapy market size was valued at USD 4.6 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 20.2% from 2021 to 2028. With the approval of Yescarta, Kymriah, and Tecartus, several companies have shifted their business models from the development of protein and small molecule-based treatments to adoptive therapies. This has driven strategic investments by the public as well as private agencies in this space, thereby driving the market for T-cell therapy.

Germany T-cell therapy market size, by therapy type, 2017 - 2028 (USD Million)

The increasing approvals coupled with expanding manufacturing capabilities are anticipated to intensify the market competition in T-cell therapy companies in the coming years. For instance, in December 2020, the European Medicine Agency issued a marketing authorization to Kite Pharma’s Tecartus – the only CAR-T therapeutic product for mantle cell lymphoma.

Furthermore, the global COVID-19 pandemic has triggered the investment flow in deciphering the application of T-cell therapies in viral infection research. A study published in December 2020 demonstrated the potential of this therapy to treat high-risk COVID-19 patients. Similarly, in September 2020, the U.S. FDA has cleared the IND application for ALVR109 to treat COVID-19 patients. This is likely to increase the adoption of T-cell therapeutics for viral infections.

Currently, the cancer immunotherapy arena widely employs T-cell based mechanism, due to a higher success rate. As of June 2020, more than 350 CAR-T clinical trials have been registered in China. This data indicates the growing importance of Chimeric Antigen Receptor therapy in cancer treatment. Also, the majority of operating players are investing in CD19 CAR-T therapies to enhance their market positions in the near future.

The expanding gene therapy marketspace is playing a vital role in the success of CAR-T therapies. With increasing investments in the gene therapy arena, this space is expected to witness constant growth. The companies such as Novartis AG are actively engaged in exploring the potential of CAR-T-based gene therapies for several chronic indications.

COVID-19 Impact: Success of Kymriah & Yescarta propel the market revenue

Pandemic Impact

Post COVID Outlook

Approval of Tecartus in July 2020 for treatment of mantle cell lymphoma drives the commercial market segment

Due to current ambiguity across the supply chain caused due to COVID-19 pandemic, a number of key players are adopting digital alternatives for management of cell therapy supply chain, which is anticipated to increase in the coming months.

CAR-T cell therapy are the key driving segment and witnessed a year-over-year growth of 37% in 2020 by virtue of Kymriah, Yescarta, Tecartus, along with other piepilne candidate programs

Supply chain solution providers, such as TrakCel, would witness increase in strategic alliances with therapy developers to accelerate and achieve supply chain harmonization within closed-system manufacturing


Modality Insights

The research segment dominated the market for T-cell therapy and accounted for more than 75.0% of revenue share in 2020 owing to the high number of products in the clinical development phase. A substantial number of research institutes such as Mayo Clinic are actively engaged in conducting CAR-T therapy programs thus supporting the method as a preferable method of cancer management.

Several operating entities are collaborating with research communities across the globe, resulting in the shift in focus on accelerating the development of CAR-T therapies to expand the therapeutic application landscape. For instance, in October 2020 Immuneel Therapeutics collaborated with Institut d’Investigacions Biomèdiques August Pi i Sunyer and Hospital Clínic de Barcelona for the development and commercialization of CAR-T therapy in India.

On the other hand, regulatory bodies are making focused efforts to propel the commercial use of these therapies in clinical and hospital settings. In August 2020, the Centers for Medicare and Medicaid Services (CMS) policies for reimbursement and coverage of CAR-T cell therapy. This policy increased the payment received to 65% of the total cost. This would spur commercial revenue growth.

Therapy Type Insights

In 2020, CAR T-cell therapy segment dominated the market for T-cell therapy and accounted for the largest revenue share of 82.0% in 2020. This is owing to the exponential rise in the number of clinical trials for CAR-T therapies and the increasing involvement of key players in this arena. A substantial number of new entrants and academic institutions are conducting clinical trials for CAR-T therapeutic products for different as well as same indications, consequently supporting the dominance of the segment.

Advancements in CAR-T therapy manufacturing enhanced the uptake of these therapies in the treatment of various cancers. The emergence of new approaches such as second-generation, next-generation CAR-T immunotherapy may overcome the challenges like resistance, side effects thus, leading to growth in organic revenue generation.

Besides this, T-cell receptor-based therapies pegged the second position in the global space owing to their potential in the treatment of solid tumors. This segment is gaining significant attention for the treatment of melanoma. Adaptimmune is one of the companies that focuses on TCR therapy for melanoma in collaboration with GlaxoSmithKline.

Indication Insights

In 2020, the hematologic malignancies segment dominated the market for T-cell therapy and accounted for a 49.0% revenue share. The CAR-T-cell therapies have been predominantly used to treat hematological malignancies including lymphoma, leukemia, and myeloma. Given the high number of market entities entering the market and high fixed costs of autologous cell manufacturing, the segment is expected to witness high market competition in the near future.

Global T-cell therapy market share, by indication, 2020 (%)

The CAR-T cell therapies have made remarkable advancements in hematological malignancies, resulting in segment saturation in terms of number of market players operating in the segment. As a result, several competitors are now shifting their focus on the development of treatments for solid tumors to capitalize on the untapped avenues of the market. The development of affordable and effective therapy for solid tumors presents lucrative opportunities for the operating key stakeholders.

Viral infections such as COVID-19 and HIV have expanded the landscape of T-cell therapies. Several CARs targeting viral infections have made tremendous progress in recent years. Anti-HIV CAR-T cell therapy has reached clinical trial whereas others such as HCV, HBV are in pre-clinical development. This is anticipated to spur the revenue flow in non-cancer indications.

Regional Insights

North America dominated the T-cell therapy market and accounted for the largest revenue share of around 40.0% in 2020. The presence of strong research, as well as a commercial base coupled with a high number of clinical trials being conducted for T-cell therapies in the U.S., has majorly contributed to the dominance of the market in the region.

Furthermore, the increasing number of regulatory approvals in the U.S. and Canada along with the changing reimbursement scenario in the region has also accelerated the uptake of these therapies leading to significant market growth. In addition, the presence of a substantial number of medical centers offering CAR-T cell therapies also supports the regional market growth.

In recent years, China has emerged as a potential market for CAR-T therapies with the highest number of registered clinical trials pertaining to these therapies. Focused efforts on government investment and reforms in the country have resulted in significant growth consequently exhibiting the fastest CAGR in the region.

Key Companies & Market Share Insights

The increasing number of companies involved in the development of CAR-T therapies is anticipated to boost the competitive landscape of the T-cell therapy space. As of now Kite Pharma and Novartis AG have dominated the market for T-cell therapy with innovations and new product developments.

Juno Therapeutics, Adaptimmune, NantKwest, Cabaletta Bio, Celgene, Bellicum Pharmaceuticals, TScan Therapeutics, GigaGen, and Tessa Therapeutics are some of the emerging companies in the arena that are engaged in the development of T-cell therapies to cover various types of oncology indications.

Moreover, the growing investment flows in this space have resulted in the entry of conventional drug developers such as Pfizer, Merck KGaA, and Amgen in this field. The acquisition of Kiadis Pharma by Sanofi depicts the growing interest of global pharmaceutical companies in this space. Some of the prominent players in the T-cell therapy market include:

  • Novartis AG

  • Merck KGaA

  • Gilead Sciences Inc.

  • TCR2 Therapeutics Inc

  • Bluebird Bio Inc.

  • Sorrento Therapeutics

  • Fate Therapeutics

  • Pfizer Inc.

  • Amgen

  • Celgene Corporation

T-cell Therapy Market Report Scope

Report Attribute


Market size value in 2021

USD 6.4 billion

Revenue forecast in 2028

USD 20.3 billion

Growth Rate

CAGR of 20.2% from 2021 to 2028

Base year for estimation


Historical data

2017 - 2019

Forecast period

2021 - 2028

Quantitative units

Revenue in USD million and CAGR from 2021 to 2028

Report coverage

Revenue forecast, company share, competitive landscape, growth factors, and trends

Segment covered

Modality, therapy type, indication, region

Regional scope

North America; Europe; Asia Pacific; Latin America; MEA

Country scope

U.S.; Canada; Germany; U.K.; China; Japan; Brazil; South Africa

Key companies profiled

Novartis AG; Merck KGaA; Gilead Sciences, Inc.; TCR2 Therapeutics Inc.; Bluebird Bio Inc.; Sorrento Therapeutics; Fate Therapeutics; Pfizer Inc.; Amgen; Celgene Corporation

Customization scope

If you need specific market information, which is not currently within the scope of the report, we will provide it to you as a part of the customization

Pricing and purchase options

Avail customized purchase options to meet your exact research needs. Explore purchase options

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2028. For the purpose of this study, Grand View Research has segmented the global T-cell therapy market report on the basis of modality, therapy type, indication, and region:

  • Modality Outlook (Revenue, USD Million, 2017 - 2028)

    • Research

    • Commercialized

  • Therapy Type Outlook (Revenue, USD Million, 2017 - 2028)

    • CAR T-cell Therapy

    • T Cell Receptor (TCR)-based

    • Tumor Infiltrating Lymphocytes (TIL)-based

  • Indication Outlook (Revenue, USD Million, 2017 - 2028)

    • Hematologic Malignancies

      • Lymphoma

      • Leukemia

      • Myeloma

    • Solid Tumors

      • Melanoma

      • Brain & Central Nervous System

      • Liver Cancer

      • Others

    • Others

  • Regional Outlook (Revenue, USD Million, 2017 - 2028)

    • North America

      • U.S.

      • Canada

    • Europe

      • Germany

      • U.K.

    • Asia Pacific

      • Japan

      • China

    • Latin America

      • Brazil

    • Middle East and Africa (MEA)

      • South Africa

Frequently Asked Questions About This Report

gvr icn


gvr icn

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

gvr icn


We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

Contact us now to get our best pricing.

esomar icon

ESOMAR certified & member

D&B icon

Leading SME award by D&B

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.

great place to work icon